See more : Victory Metals Limited (VTM.AX) Income Statement Analysis – Financial Results
Complete financial analysis of MERCK Kommanditgesellschaft auf Aktien (MKGAF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MERCK Kommanditgesellschaft auf Aktien, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Fujian Start Group Co.Ltd (600734.SS) Income Statement Analysis – Financial Results
- Anixa Biosciences, Inc. (ANIX) Income Statement Analysis – Financial Results
- Georgia Capital PLC (GRGCF) Income Statement Analysis – Financial Results
- Imperium Technology Group Limited (0776.HK) Income Statement Analysis – Financial Results
- Stereotaxis, Inc. (STXS) Income Statement Analysis – Financial Results
MERCK Kommanditgesellschaft auf Aktien (MKGAF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.merckgroup.com
About MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and electronics sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat neurology and immunology, oncology, fertility, and cardiology metabolism and endocrinology. The company also supplies products, tools, and services for research laboratories, pharma and biotech production, and industrial and testing laboratories. In addition, it offers material for integrated circuits, liquid crystals, organic light-emitting diodes, photoresists, smart antenna, and liquid crystal glazing solutions, as well as effect pigments for use in automotive coatings, cosmetics, industrial, and plastic applications. It has strategic alliances with Pfizer Inc.; agreement with Novartis AG; and license agreements with Debiopharm International SA and MoonLake Immunotherapeutics AG. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.99B | 22.23B | 19.69B | 17.53B | 16.15B | 14.84B | 15.33B | 15.02B | 12.84B | 11.50B | 11.10B | 11.17B | 10.28B | 9.29B | 7.75B | 7.56B | 7.06B | 6.26B | 5.87B | 5.34B | 7.20B | 7.40B |
| Cost of Revenue | 8.56B | 8.53B | 7.35B | 6.84B | 6.01B | 5.38B | 5.32B | 5.20B | 4.08B | 4.06B | 3.56B | 3.74B | 2.79B | 2.39B | 2.03B | 1.91B | 1.78B | 2.41B | 2.37B | 2.25B | 3.57B | 3.79B |
| Gross Profit | 12.44B | 13.71B | 12.34B | 10.70B | 10.15B | 9.45B | 10.01B | 9.82B | 8.77B | 7.44B | 7.54B | 7.44B | 7.49B | 6.91B | 5.72B | 5.65B | 5.28B | 3.84B | 3.50B | 3.09B | 3.63B | 3.61B |
| Gross Profit Ratio | 59.23% | 61.65% | 62.66% | 61.02% | 62.82% | 63.72% | 65.29% | 65.38% | 68.26% | 64.66% | 67.92% | 66.55% | 72.87% | 74.32% | 73.81% | 74.78% | 74.78% | 61.43% | 59.64% | 57.87% | 50.40% | 48.72% |
| Research & Development | 2.45B | 2.52B | 2.41B | 2.29B | 2.27B | 2.23B | 2.14B | 1.98B | 1.71B | 1.70B | 1.50B | 1.51B | 1.52B | 1.40B | 1.34B | 1.23B | 1.03B | 751.60M | 713.00M | 599.00M | 604.60M | 608.20M |
| General & Administrative | 1.39B | 1.31B | 1.24B | 1.19B | 1.15B | 993.00M | 930.00M | 854.00M | 719.90M | 608.60M | 562.40M | 552.20M | 1.01B | 478.20M | 424.90M | 446.20M | 444.70M | 386.70M | 354.70M | 329.20M | 412.40M | 468.00M |
| Selling & Marketing | 3.91B | 4.10B | 3.71B | 3.57B | 3.65B | 3.41B | 3.69B | 3.50B | 3.27B | 2.39B | 2.33B | 2.41B | 2.39B | 2.23B | 2.27B | 2.10B | 1.93B | 1.48B | 1.47B | 1.34B | 1.72B | 1.77B |
| SG&A | 5.31B | 5.40B | 4.96B | 4.76B | 4.81B | 4.40B | 4.62B | 4.35B | 3.99B | 2.99B | 2.89B | 2.96B | 3.40B | 2.71B | 2.70B | 2.54B | 2.38B | 1.86B | 1.82B | 1.67B | 2.13B | 2.24B |
| Other Expenses | 1.08B | 1.03B | 777.00M | 841.00M | 767.00M | 521.00M | 681.00M | 431.00M | 342.80M | 65.80M | 62.70M | 70.80M | 68.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.83B | 8.95B | 8.14B | 7.89B | 7.84B | 7.58B | 7.63B | 7.53B | 6.60B | 5.68B | 5.38B | 5.55B | 6.50B | 5.80B | 5.07B | 4.52B | 4.30B | 2.74B | 2.62B | 2.05B | 3.05B | 3.11B |
| Cost & Expenses | 17.38B | 17.48B | 15.49B | 14.72B | 13.85B | 12.97B | 12.95B | 12.73B | 10.68B | 9.74B | 8.94B | 9.28B | 9.29B | 8.19B | 7.10B | 6.43B | 6.08B | 5.15B | 4.99B | 4.30B | 6.62B | 6.90B |
| Interest Income | 121.00M | 71.00M | 46.00M | 39.00M | 66.00M | 55.00M | 26.00M | 20.00M | 32.00M | 30.60M | 30.10M | 35.60M | 57.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 272.00M | 235.00M | 272.00M | 387.00M | 476.00M | 339.00M | 348.00M | 342.00M | 348.80M | 222.70M | 248.00M | 301.20M | 319.10M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.88B | 1.80B | 1.71B | 1.76B | 1.91B | 1.75B | 1.76B | 1.81B | 1.51B | 1.36B | 1.46B | 1.40B | 1.60B | 1.26B | 1.00B | 1.22B | 923.60M | 303.00M | 289.50M | 375.00M | 470.50M | 425.20M |
| EBITDA | 5.69B | 6.55B | 5.96B | 4.73B | 4.16B | 3.60B | 4.25B | 4.43B | 3.35B | 3.14B | 3.10B | 2.41B | 2.76B | 2.36B | 1.65B | 2.35B | 1.90B | 1.10B | 1.17B | 1.42B | 1.01B | 920.00M |
| EBITDA Ratio | 27.08% | 30.33% | 30.28% | 26.97% | 26.18% | 25.00% | 27.29% | 27.90% | 28.19% | 27.73% | 33.03% | 29.29% | 23.65% | 25.45% | 21.65% | 36.34% | 37.90% | 19.00% | 18.72% | 26.57% | 17.32% | 13.20% |
| Operating Income | 3.61B | 4.47B | 4.18B | 2.99B | 2.12B | 1.73B | 2.53B | 2.48B | 1.84B | 1.76B | 1.61B | 963.60M | 985.10M | 1.11B | 620.90M | 731.40M | 975.70M | 1.11B | 955.60M | 1.04B | 579.30M | 494.80M |
| Operating Income Ratio | 17.19% | 20.12% | 21.23% | 17.02% | 13.13% | 11.64% | 16.47% | 16.51% | 14.35% | 15.32% | 14.52% | 8.62% | 9.59% | 11.94% | 8.01% | 9.68% | 13.83% | 17.67% | 16.28% | 19.54% | 8.04% | 6.69% |
| Total Other Income/Expenses | -125.00M | -187.00M | -255.00M | -355.00M | -385.00M | -266.00M | -294.00M | -327.00M | -356.00M | -205.00M | -222.20M | -1.13B | -293.30M | -248.30M | -159.00M | -156.50M | -1.09B | 167.90M | 11.90M | -82.70M | -156.70M | -83.20M |
| Income Before Tax | 3.48B | 4.29B | 3.92B | 2.63B | 1.74B | 1.46B | 2.22B | 2.15B | 1.49B | 1.56B | 1.39B | 709.00M | 851.10M | 861.10M | 486.40M | 574.90M | -110.90M | 1.27B | 893.40M | 960.80M | 422.60M | 411.60M |
| Income Before Tax Ratio | 16.60% | 19.28% | 19.93% | 15.00% | 10.74% | 9.85% | 14.51% | 14.34% | 11.57% | 13.54% | 12.52% | 6.35% | 8.28% | 9.27% | 6.28% | 7.61% | -1.57% | 20.35% | 15.22% | 17.99% | 5.87% | 5.56% |
| Income Tax Expense | 650.00M | 948.00M | 859.00M | 637.00M | 440.00M | 368.00M | -386.00M | 521.00M | 368.00M | 392.20M | 179.50M | 130.00M | 222.10M | 219.60M | 109.70M | 195.80M | -23.10M | 272.20M | 220.70M | 288.90M | 204.90M | 196.40M |
| Net Income | 2.82B | 3.33B | 3.06B | 1.99B | 1.32B | 3.37B | 2.61B | 1.63B | 1.12B | 1.16B | 1.20B | 566.70M | 606.50M | 641.50M | 376.70M | 379.10M | 3.52B | 1.00B | 672.70M | 671.90M | 217.70M | 215.20M |
| Net Income Ratio | 13.45% | 14.96% | 15.52% | 11.33% | 8.17% | 22.74% | 17.00% | 10.84% | 8.68% | 10.06% | 10.84% | 5.07% | 5.90% | 6.90% | 4.86% | 5.02% | 49.88% | 16.00% | 11.46% | 12.58% | 3.02% | 2.91% |
| EPS | 6.49 | 7.65 | 7.03 | 4.57 | 3.04 | 7.76 | 5.99 | 3.75 | 2.56 | 2.66 | 2.77 | 1.31 | 1.40 | 1.46 | 0.84 | 0.85 | 8.11 | 2.54 | 1.67 | 1.71 | 0.57 | 0.58 |
| EPS Diluted | 6.50 | 7.65 | 7.03 | 4.57 | 3.04 | 7.76 | 5.99 | 3.75 | 2.56 | 2.66 | 2.77 | 1.31 | 1.40 | 1.46 | 0.84 | 0.85 | 8.11 | 2.54 | 1.67 | 1.71 | 0.57 | 0.58 |
| Weighted Avg Shares Out | 435.13M | 434.78M | 434.78M | 434.78M | 434.78M | 434.78M | 434.78M | 434.40M | 434.78M | 435.08M | 434.01M | 434.25M | 434.77M | 434.80M | 434.80M | 434.80M | 431.80M | 388.00M | 393.65M | 385.12M | 366.84M | 349.37M |
| Weighted Avg Shares Out (Dil) | 434.78M | 434.78M | 434.78M | 434.78M | 434.78M | 434.78M | 434.89M | 434.40M | 435.55M | 435.08M | 434.01M | 434.25M | 434.77M | 434.80M | 434.80M | 434.80M | 431.80M | 388.00M | 393.65M | 385.12M | 366.84M | 349.37M |
Is Merck KGaA (MKKGY) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong...
Merck KGaA (MKGAF) Q3 2024 Earnings Call Transcript
Merck KGaA (OTCPK:MKGAF) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET Company Participants Constantin Fest - Head of Investor Relations Belen Lopez - Chair of Executive Board & CEO Helene von Roeder - CFO Peter Guenter -...
Is Merck KGaA (MKKGY) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong...
AI is driving semiconductor industry, says CEO Electronics at Merck KgaA
Kai Beckmann, a member of the executive board and the CEO Electronics at Merck KgaA, discusses the use of AI in the semiconductor industry.
Merck KGaA (MKGAF) Q2 2024 Earnings Call Transcript
Merck KGaA (OTCPK:MKGAF) Q2 2024 Results Conference Call August 1, 2024 8:00 AM ET Company Participants Constantin Fest - Head of Investor Relations Belen Lopez - Chair of Executive Board & CEO Helene von Roeder - CFO Peter Guenter -...
Merck KGaA: The Drop Makes The Upside All The Sweeter
Merck KGaA remains undervalued with strong fundamentals and diverse business portfolio in healthcare, life sciences, and electronics. The company has above-average margins compared to the broader market, indicating outperformance potential. Despite volatility, Merck KGaA presents an interesting upside for investors.
Merck KGaA shares slump on neck cancer trial failure
Merck KGaA shares fell by as much as 10% after the company announced the termination of its phase III trial of xevinapant in neck cancer. The interim analysis revealed that the study is unlikely to meet its primary objective, prompting the...
Merck KGaA, Darmstadt, Germany, Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the discontinuation of the Phase III randomized TrilynX study evaluating xevinapant plus chemoradiotherapy (CRT) in patients with unresected locally advanced squamous cell carcinoma of the head...
Merck KGaA (MKGAF) Upgraded to Buy: Here's What You Should Know
Merck KGaA (MKGAF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What Makes Merck KGaA (MKGAF) a Good Fit for 'Trend Investing'
Merck KGaA (MKGAF) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Source: https://incomestatements.info
Category: Stock Reports